Kindred Biosciences, Inc. (NASDAQ:KIN) shares rose Wednesday after the company disclosed results from its long-acting Interleukin-31 antibody PK study.
The San Francisco-based Kindred, a biopharmaceutical company focused on saving and improving the lives of pets, today unveiled positive results in a new long-acting interleukin (IL)-31 antibody program (KIND-039) that integrates the company's novel half-life extension technology.
The company news release says results from the pharmacokinetic study of the molecule demonstrate that the fully caninized, high-affinity antibody has up to a three-fold longer half-life compared to tirnovetmab. This extended half-life is expected to allow for up to three-fold longer interval between dosing.
CEO Richard Chin remarked, "One of the main unmet needs in the canine dermatitis market is reduced dosing frequency and increased convenience. With these exciting results, we believe our new long-acting IL-31 antibody program has the potential to become a best-in-class therapeutic and the treatment of choice in the large and growing dermatitis market.
"We expect to initiate the pivotal study for this molecule as early as the end of this year."
KindredBio's half-life extension technology is designed to improve therapeutic performance in a multitude of ways. The reduced dosing frequency and/or amount of dosing can lead to improved patient convenience and compliance. The technology can also significantly reduce the cost of goods and enhance profitability and market positioning.
KIN shares improved 22 cents, or 4.7%, to $4.93.
